PARIS, FRANCE, 22 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an…
– Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody – Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of pivotal Phase…
– Complete SAFE KIDNEY II data confirm sustained reduction in viral load and resolution of biopsy-proven BKPyV-associated nephropathy with continued antiviral effect to 38 weeks – Systematic literature review demonstrates…
– First in class therapeutic antibody, potravitug, for BK polyomavirus infection showed consistent reduction in viral load and biopsy-proven BKPyVAN in a Phase II study in kidney transplant recipients– Propensity…
– First conceptual model demonstrating the impact of BK polyomavirus on the health-related quality of life of kidney transplant recipients– Study conducted in partnership with Northwestern University and presented at…
– Orphan designation confers market exclusivity, regulatory and financial benefits for medicines intended to treat rare diseases– Recognizes both medical plausibility of the initial clinical data and that potravitug targets…
– Long term follow-up data shows a sustained and improved (vs. week 20) benefit of potravitug on BK polyomavirus viral load in kidney transplant recipients at week 38 (study end)–…
Our CEO, Erik van den Berg recently sat down with John Simboli of the BioBoss podcast, where he discussed his career journey from AM-Pharma to Memo Therapeutics and what attracted…
1. Can you please introduce yourself, explain your role and tell us about the mission of the Forum for Collaborative Research, particularly the Transplantation Associated Virus Infections (TAVI) forum. I…
Dr Joseph Gaut, Ladenson Professor of Pathology & Immunology at Washington University School of Medicine discusses his thoughts on the recently completed Phase II clinical trial of potravitug, a highly…
– First-in-human, Phase I, randomized, placebo-controlled study, successfully demonstrated safety and tolerability of potravitug in healthy volunteers– The Company recently announced the results from its Phase II placebo-controlled clinical trial…
Kevin Fowler, kidney transplant recipient and Principal of The Voice of the Patient, discusses his role as a consultant to Memo Therapeutics, contributing to site engagement and enrollment for the…
Archived press releases
Memo Therapeutics AG’s assets not related to potravitug, will be transferred to a newly incorporated company, Memorises Bio, retained by Memo Therapeutics AG’s shareholders.
This archive will be maintained until the launch of the Memorises Bio website. For information regarding topics unrelated to potravitug, please contact the Memorises Bio team.
– Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technology– Agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the option by CSL, a license…
1. Can you talk a bit about how your scientific training and industry experience led to your current role at Memo Therapeutics AG? I’m a bioengineer by training, and the…